CN113817060B - 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 - Google Patents

用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 Download PDF

Info

Publication number
CN113817060B
CN113817060B CN202111238485.4A CN202111238485A CN113817060B CN 113817060 B CN113817060 B CN 113817060B CN 202111238485 A CN202111238485 A CN 202111238485A CN 113817060 B CN113817060 B CN 113817060B
Authority
CN
China
Prior art keywords
gly
ser
leu
arg
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111238485.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113817060A (zh
Inventor
唐纳德·E·斯汤顿
陆满晴
李志杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiali Medical Technology Guangzhou Co ltd
Original Assignee
Jiali Medical Technology Guangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiali Medical Technology Guangzhou Co ltd filed Critical Jiali Medical Technology Guangzhou Co ltd
Priority to CN202111238485.4A priority Critical patent/CN113817060B/zh
Publication of CN113817060A publication Critical patent/CN113817060A/zh
Application granted granted Critical
Publication of CN113817060B publication Critical patent/CN113817060B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202111238485.4A 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞 Active CN113817060B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111238485.4A CN113817060B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662276855P 2016-01-09 2016-01-09
US62/276,855 2016-01-09
CN202111238485.4A CN113817060B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN201780005758.6A CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
PCT/US2017/012648 WO2017120557A1 (en) 2016-01-09 2017-01-07 Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780005758.6A Division CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Publications (2)

Publication Number Publication Date
CN113817060A CN113817060A (zh) 2021-12-21
CN113817060B true CN113817060B (zh) 2024-03-08

Family

ID=59274048

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111238485.4A Active CN113817060B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238201.1A Active CN113817059B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238599.9A Active CN113912725B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN201780005758.6A Active CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202111238201.1A Active CN113817059B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN202111238599.9A Active CN113912725B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN201780005758.6A Active CN108778327B (zh) 2016-01-09 2017-01-07 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞

Country Status (8)

Country Link
US (1) US11207419B2 (enExample)
EP (1) EP3400013A4 (enExample)
JP (3) JP6974348B2 (enExample)
KR (1) KR20180127966A (enExample)
CN (4) CN113817060B (enExample)
AU (1) AU2017206089B2 (enExample)
IL (1) IL260474B (enExample)
WO (1) WO2017120557A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210116456A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Compositions and methods for diagnosis and treatment of cancer
US20210115152A1 (en) * 2018-05-16 2021-04-22 Arbele Limited Composition of bispecific antibodies and method of use thereof
CN113891718B (zh) * 2019-02-21 2025-01-28 杭州天康麦生物技术有限公司 人工免疫监视嵌合抗原受体(ai-car)及其表达细胞
TWI717880B (zh) 2019-10-24 2021-02-01 中國醫藥大學附設醫院 Hla-g特異性嵌合抗原受體、核酸、hla-g特異性嵌合抗原受體表達質體、表達hla-g特異性嵌合抗原受體細胞、其用途以及用於治療癌症之醫藥組合物
CN114786720B (zh) * 2019-12-05 2025-08-22 艾贝乐医药科技有限公司 TriAx抗体的组合物及其制备和使用方法
US12275798B2 (en) 2021-06-17 2025-04-15 Boehringer Ingelheim International Gmbh Tri-specific binding molecules
EP4413366A4 (en) * 2021-10-08 2025-09-10 Tiberias Tech Hk Limited TIBTECH METHODS AND COMPOSITIONS FOR THE DETECTION OF CDH17
CA3240301A1 (en) * 2021-12-07 2023-06-15 Dennis Slamon Cdh17 antibodies and methods of treating cancer
CN113999308B (zh) * 2021-12-30 2022-03-11 深圳市人民医院 靶向钙粘蛋白17的纳米抗体及其应用
EP4615870A1 (en) 2022-11-11 2025-09-17 Ospedale San Raffaele S.r.l. Cdh17 car
WO2024175093A1 (en) * 2023-02-23 2024-08-29 Hansoh Bio Llc Antibodies, antigen-binding fragments and methods of use
WO2024220437A2 (en) * 2023-04-17 2024-10-24 Arbele Limited Compositions and methods for determining the effects of t cell engager
TW202509083A (zh) * 2023-05-24 2025-03-01 大陸商普眾發現醫藥科技（上海）有限公司 抗體及其抗體－藥物偶聯物
TW202517672A (zh) * 2023-09-22 2025-05-01 大陸商樂普生物科技股份有限公司 抗ｃｄｈ１７抗體及其用途
CN120230211A (zh) * 2023-12-29 2025-07-01 广东菲鹏制药股份有限公司 抗cdh17抗体或其抗原结合片段及其应用
WO2025242099A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体偶联药物及其用途
WO2025242100A1 (zh) * 2024-05-21 2025-11-27 康诺亚生物医药科技（成都）有限公司 针对cdh17的抗体及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616933A (zh) * 2006-10-19 2009-12-30 赛诺菲-安万特 用于治疗癌症的新型抗-cd38抗体
CN101663322A (zh) * 2006-12-14 2010-03-03 株式会社未来创药研究所 抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断
CN102482353A (zh) * 2009-04-20 2012-05-30 牛津生物疗法有限公司 特异于钙粘素-17的抗体
CN102483414A (zh) * 2008-10-09 2012-05-30 香港大学 作为肝癌诊断标记和治疗靶标的钙黏着蛋白-17
CN103534268A (zh) * 2010-10-20 2014-01-22 牛津生物疗法有限公司 抗体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JP4754219B2 (ja) * 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
CA2714413C (en) 2008-02-08 2017-01-24 Immunas Pharma, Inc. Antibody capable of binding specifically to ab-oligomer, and use thereof
RU2011103199A (ru) * 2008-06-30 2012-08-10 Онкотерапи Сайенс, Инк. (Jp) Антитела против cdh3, меченные радиоизотопной меткой, и их применение
BR112012020116B8 (pt) * 2010-02-10 2023-01-10 Perseus Proteomics Inc Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer
BR112013001062A2 (pt) * 2010-07-15 2016-05-24 Synovex Corp anticorpos humanizados que visam o domínio ec1 de caderina-11 e composições e métodos relacionados
EP2710042A2 (en) * 2011-05-16 2014-03-26 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
ES2728936T3 (es) * 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
KR102357961B1 (ko) * 2013-12-17 2022-02-08 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101616933A (zh) * 2006-10-19 2009-12-30 赛诺菲-安万特 用于治疗癌症的新型抗-cd38抗体
CN101663322A (zh) * 2006-12-14 2010-03-03 株式会社未来创药研究所 抗紧密连接蛋白3单克隆抗体以及使用该抗体的癌症的治疗和诊断
CN102483414A (zh) * 2008-10-09 2012-05-30 香港大学 作为肝癌诊断标记和治疗靶标的钙黏着蛋白-17
CN102482353A (zh) * 2009-04-20 2012-05-30 牛津生物疗法有限公司 特异于钙粘素-17的抗体
CN103534268A (zh) * 2010-10-20 2014-01-22 牛津生物疗法有限公司 抗体

Also Published As

Publication number Publication date
CN108778327A (zh) 2018-11-09
CN113817059B (zh) 2024-03-08
CN113817060A (zh) 2021-12-21
AU2017206089A1 (en) 2018-08-30
CN113912725A (zh) 2022-01-11
JP2022036939A (ja) 2022-03-08
CN113912725B (zh) 2024-03-08
KR20180127966A (ko) 2018-11-30
EP3400013A1 (en) 2018-11-14
JP7482287B2 (ja) 2024-05-13
JP2019518721A (ja) 2019-07-04
JP6974348B2 (ja) 2021-12-01
EP3400013A4 (en) 2019-09-11
JP2023109790A (ja) 2023-08-08
WO2017120557A1 (en) 2017-07-13
IL260474B (en) 2020-08-31
CN108778327B (zh) 2021-11-05
CN113817059A (zh) 2021-12-21
AU2017206089B2 (en) 2020-04-16
JP7275232B2 (ja) 2023-05-17
US20190046655A1 (en) 2019-02-14
US11207419B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
CN113817060B (zh) 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
CN112512575B (zh) 双特异性抗体组合物及其使用方法
US9334330B2 (en) Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for the treatment of certain cancers
TW201639887A (zh) 抗－ｄｌｌ３嵌合抗原受體及其使用方法
WO2016133059A1 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
KR20240125026A (ko) Gprc5d를 표적으로 하는 완전 인간 항체와 키메라 항원 수용체(car) 및 이의 용도
JP2024513262A (ja) Ｎｋｐ４６及びｃｄ３８を標的とする二重特異性抗体、並びにその使用方法
JP2025526677A (ja) Ｂ７－ｈ３抗原結合性分子
US20220315665A1 (en) Chimeric antigen receptors targeting glypican-2
HK1262482A1 (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
EP4567046A1 (en) Antibody targeting egfrviii and use thereof in cell immunotherapy
HK1262482B (zh) 用於癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
EP4588939A1 (en) Interleukin-13 receptor subunit alpha-2 (il13ralpha2) targeting moieties for the treatment and prevention of il13ralpha2-positive cancer
TW202535920A (zh) 程序性死亡配體1（pd-l1）嵌合抗原受體及其應用
CA3218832A1 (en) Combined therapy using anti-cd300c antibody
HK40010512A (en) Bcma-targeting antibody and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant